Efficacy of EGFR tyrosine kinase inhibitors in patients having EGFR-activating mutations with or without BIM polymorphisms

被引：0
|
作者：
Ryo Ariyasu
Noriko Yanagitani
Kenichi Tadokoro
Toshikazu Yamaguchi
Ken Uchibori
Satoru Kitazono
Naoya Fujita
Ryohei Katayama
Makoto Nishio
机构：
[1] The Cancer Institute Hospital,Department of Thoracic Medical Oncology
[2] Japanese Foundation for Cancer Research,Cancer Chemotherapy Center
[3] BML,undefined
[4] INC,undefined
[5] Japanese Foundation for Cancer Research,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2020年 / 86卷
关键词：
deletion polymorphism; single nucleotide polymorphism; Non-small cell lung cancer; EGFR-TKI;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：517 / 525
页数：8
相关论文
共 50 条
  • [1] Efficacy of EGFR tyrosine kinase inhibitors in patients having EGFR-activating mutations with or without BIM polymorphisms
    Ariyasu, Ryo
    Yanagitani, Noriko
    Tadokoro, Kenichi
    Yamaguchi, Toshikazu
    Uchibori, Ken
    Kitazono, Satoru
    Fujita, Naoya
    Katayama, Ryohei
    Nishio, Makoto
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2020, 86 (04) : 517 - 525
  • [2] Erlotinib has better efficacy than gefitinib in adenocarcinoma patients without EGFR-activating mutations, but similar efficacy in patients with EGFR-activating mutations
    Wu, Wen-Shuo
    Chen, Yuh-Min
    Tsai, Chun-Ming
    Shih, Jen-Fu
    Chiu, Chao-Hua
    Chou, Kun-Ta
    Lai, Shinn-Liang
    Wu, Chieh-Hung
    Luo, Yung-Hung
    Huang, Chu-Yun
    Lee, Yu-Chin
    Perng, Reury-Perng
    Whang-Peng, Jacqueline
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2012, 3 (02) : 207 - 213
  • [3] Compound EGFR Mutations and Response to EGFR Tyrosine Kinase Inhibitors
    Kobayashi, Susumu
    Canepa, Hannah M.
    Bailey, Alexandra S.
    Nakayama, Sohei
    Yamaguchi, Norihiro
    Goldstein, Michael A.
    Huberman, Mark S.
    Costa, Daniel B.
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 (01) : 118 - 122
  • [4] Drug Tolerance to EGFR Tyrosine Kinase Inhibitors in Lung Cancers with EGFR Mutations
    Suda, Kenichi
    Mitsudomi, Tetsuya
    CELLS, 2021, 10 (07)
  • [5] Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors
    Gazdar, A. F.
    ONCOGENE, 2009, 28 : S24 - S31
  • [6] Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors
    A F Gazdar
    Oncogene, 2009, 28 : S24 - S31
  • [7] NSCLC Patients With Rare EGFR Mutations in Exons 18 and 19 Benefits From Treatment With EGFR Tyrosine Kinase Inhibitors
    Xu, J.
    Guo, R.
    Li, M.
    Xiang, J.
    Lizaso, A.
    Mao, X.
    Ye, J.
    Xu, C.
    Chen, K.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S633 - S633
  • [8] Sequencing of EGFR Tyrosine Kinase Inhibitors
    Park, Keunchil
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S83 - S85
  • [9] Efficacy of EGFR tyrosine kinase inhibitors in non-small cell lung cancer patients harboring different types of EGFR mutations: A retrospective analysis
    Liu, Hua-li
    Han, Guang
    Peng, Min
    Weng, Yi-ming
    Yuan, Jing-ping
    Yang, Gui-fang
    Yu, Jin-ming
    Song, Qi-bin
    JOURNAL OF HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY-MEDICAL SCIENCES, 2017, 37 (06) : 864 - 872
  • [10] Efficacy of EGFR tyrosine kinase inhibitors in non-small cell lung cancer patients harboring different types of EGFR mutations: A retrospective analysis
    Hua-li Liu
    Guang Han
    Min Peng
    Yi-ming Weng
    Jing-ping Yuan
    Gui-fang Yang
    Jin-ming Yu
    Qi-bin Song
    Current Medical Science, 2017, 37 : 864 - 872
12345